Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Mateos, M.V. (María Victoria); Hernandez, J.M. (J. M.); Hernandez, M.T. (Miguel Teodoro); Gutierrez, N.C. (Norma C.); Palomera, L. (Luis); Fuertes, M. (M.); Garcia-Sanchez, P. (P.); Lahuerta, J.J. (Juan José); Rubia, J. (Javier) de la; Terol, M.J. (María José); Sureda-Balari, A. M. (Anna Maria); Bargay, J. (Joan); Ribas, P. (Paz); Alegre, A. (A.); Arriba, F. (Felipe) de; Oriol, A. (Albert); Carrera, D. (D,); Garcia-Laraña, J. (J.); García-Sanz, R. (Ramón); Bladé, J. (Joan); Prosper-Cardoso, F. (Felipe); Mateo, G. (Gemma); Esseltine, D.L. (D. L.); Velde, H. (Helgi) van de; San-Miguel, J.F. (Jesús F.)

Keywords:

Materias Investigacion::Ciencias de la Salud::Oncología

Issue Date:

2008

Publisher:

Fondazione Ferrata Storti

Publisher Version:

http://www.haematologica.org

ISSN:

0390-6078

Citation:

Mateos, M.-V., Hernández. J. M., Hernández, M. T., Gutiérrez, N. C. et al Haematologica 2008; 93(4): 560-565

Abstract

New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple myeloma are required. One strategy is to combine melphalan and prednisone with novel agents. We previously reported an 89% response rate, including 32% complete responses and 11% near complete responses, in our phase 1/2 study of bortezomib plus melphalan and prednisone (VMP) in 60 newly diagnosed multiple myeloma patients with a median age of 75 years. Here, we report updated time-to-events data and the impact of poor prognosis factors on outcome.

URI:

https://hdl.handle.net/10171/17831

Appears in Collections:

DA - CIMA - Hemato-oncología - Síndromes mieloproliferativos - Artículos de Revista
DA - CIMA - Medicina regenerativa - Terapia celular - Artículos de Revista
DA - CUN - Área de Terapia Celular - Artículos de revista

Files in This Item: